AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6361558 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (3 mg/kg initial dose)
Number of subjects: 38
Study 6361558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31280133 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborating toward a joint concrete goal of earning resources that could subsequently be shared
Number of subjects: 0
Study 31280133 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborating toward a joint concrete goal without earning resources
Number of subjects: 0
Study 31280133 — intervention group
Group type: COMPARATOR
Intervention: Playing a social game without earning resources
Number of subjects: 0
Study 29659585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil
Number of subjects: 282
Study 29659585 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-limb RIPC
Number of subjects: 282
Study 29659585 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 282
Study 26817441 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified nurse-delivered transitional home visit
Number of subjects: 0
Study 26817441 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25029202 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (2 μg intravenously)
Number of subjects: 67
Study 23071551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled video condition
Number of subjects: 1631
Study 23071551 — intervention group
Group type: EXPERIMENTAL
Intervention: Webpage condition
Number of subjects: 1631
Study 23071551 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1631
Study 20385996 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course intensive polychemotherapy (in blocks R1, R2, or R3) and cranial/craniospinal irradiation followed by maintenance therapy.
Number of subjects: 525
Study 20385996 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem-cell transplantation (SCT) for high-risk groups A plus poor prognosis group (PPG).
Number of subjects: 525
Study 20385996 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (not explicitly defined in the abstract).
Number of subjects: 525
Study 17288680 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 30-325 mg daily
Number of subjects: 2739
Study 17288680 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2739
Study 16235795 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned vaginal delivery
Number of subjects: 0
Study 16235795 — intervention group
Group type: COMPARATOR
Intervention: Planned caesarean section
Number of subjects: 0
Study 11925374 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm with spermicide
Number of subjects: 0
Study 11925374 — intervention group
Group type: COMPARATOR
Intervention: Diaphragm without spermicide
Number of subjects: 0
Study 10197295 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine clearance in pediatric patients with liver diseases (LD)
Number of subjects: 18
Study 10197295 — intervention group
Group type: COMPARATOR
Intervention: Caffeine clearance in healthy children
Number of subjects: 18
Study 10197295 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary molar ratio of [AFMU + 1U + 1X]/17U in pediatric patients with liver diseases (LD)
Number of subjects: 18
Study 10197295 — intervention group
Group type: COMPARATOR
Intervention: Urinary molar ratio of [AFMU + 1U + 1X]/17U in healthy children
Number of subjects: 18
Study 10197295 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary ratios of AFMU/1X and 1U/1X in pediatric patients with liver diseases (LD)
Number of subjects: 18
Study 10197295 — intervention group
Group type: COMPARATOR
Intervention: Urinary ratios of AFMU/1X and 1U/1X in healthy children
Number of subjects: 18
Study 7551881 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 20, 40, and 60 micrograms
Number of subjects: 8
Study 7551881 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 60 micrograms
Number of subjects: 8
Study 7551881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2273193 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg riboflavin daily
Number of subjects: 18
Study 2273193 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg riboflavin daily
Number of subjects: 18
Study 2273193 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 mg riboflavin (one-a-day supplement)
Number of subjects: 18
Study 2273193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 428372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling supine
Number of subjects: 30
Study 428372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling sitting
Number of subjects: 30
Study 428372 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate arm cranking standing
Number of subjects: 30
Study 428372 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking on a treadmill
Number of subjects: 30
Study 428372 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping on a bench
Number of subjects: 30
Study 31618905 — intervention group
Group type: EXPERIMENTAL
Intervention: BB536
Number of subjects: 40
Study 31618905 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BB536 and AHCC®
Number of subjects: 40
Study 31618905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31618905 — intervention group
Group type: EXPERIMENTAL
Intervention: AHCC®
Number of subjects: 40
Study 28207507 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN + SOF + RBV
Number of subjects: 533
Study 28207507 — intervention group
Group type: COMPARATOR
Intervention: SOF + RBV
Number of subjects: 533
Study 28207507 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (IFN + SOF + RBV and SOF + RBV)
Number of subjects: 533
Study 28207507 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-based regimens
Number of subjects: 533
Study 28207507 — intervention group
Group type: COMPARATOR
Intervention: RBV
Number of subjects: 533
Study 26270255 — intervention group
Group type: EXPERIMENTAL
Intervention: J-CPAP (variable flow)
Number of subjects: 170
Study 26270255 — intervention group
Group type: COMPARATOR
Intervention: B-CPAP (continuous flow)
Number of subjects: 170
Study 23337559 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 50
Study 23337559 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 50
Study 23337559 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 50
Study 21888870 — intervention group
Group type: EXPERIMENTAL
Intervention: Zednad® Tablet (500 mg cefuroxime/tablet)
Number of subjects: 24
Study 21888870 — intervention group
Group type: COMPARATOR
Intervention: Zinnat® Tablet (500 mg cefuroxime/tablet)
Number of subjects: 24
Study 19055515 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose aspirin
Number of subjects: 2338
Study 19055515 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin
Number of subjects: 2338
Study 19055515 — intervention group
Group type: EXPERIMENTAL
Intervention: Both aspirin combined groups
Number of subjects: 2338
Study 19055515 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin groups (without considering dose)
Number of subjects: 2338
Study 16738974 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron and dexamethason
Number of subjects: 210
Study 16738974 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiemetic drugs (groups 1 to 6)
Number of subjects: 210
Study 16738974 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiemetic)
Number of subjects: 210
Study 13679279 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 19
Study 13679279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10618572 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of the atrioventricular junction
Number of subjects: 156
Study 8604765 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed care joiners
Number of subjects: 814
Study 8604765 — intervention group
Group type: COMPARATOR
Intervention: Non-joiners
Number of subjects: 814
Study 8604765 — intervention group
Group type: COMPARATOR
Intervention: Indemnity plan members
Number of subjects: 814
Study 8604765 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 814
Study 1550911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levoprotiline (15 mg)
Number of subjects: 12
Study 1550911 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral levoprotiline (75 mg)
Number of subjects: 12
Study 3933019 — intervention group
Group type: EXPERIMENTAL
Intervention: cream containing l‐cysteine, glycine and dl‐threonine
Number of subjects: 22
Study 3933019 — intervention group
Group type: COMPARATOR
Intervention: cream base alone (placebo)
Number of subjects: 22
Study 30967424 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose anti-thymocyte globulin (ATG) (2.5 mg/kg)
Number of subjects: 89
Study 30967424 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG and pegylated granulocyte colony-stimulating factor (GCSF)
Number of subjects: 89
Study 30967424 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG alone
Number of subjects: 89
Study 30967424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 29499873 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring blood pressure
Number of subjects: 1182
Study 29499873 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 1182
Study 29499873 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1182
Study 29499873 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring vs Telemonitoring
Number of subjects: 1182
Study 27556735 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling counts of golden eagles using distance sampling and visual mark-recapture procedures; no specific dosage or duration mentioned as this is observational modeling.
Number of subjects: 0
Study 27556735 — intervention group
Group type: EXPERIMENTAL
Intervention: Model predictions of habitat use based on survey data from 2006-2010; no specific dosage or duration mentioned.
Number of subjects: 0
Study 27556735 — intervention group
Group type: EXPERIMENTAL
Intervention: Map predicting intensity of use by golden eagles during late summer across a ∼2 million‐km2 study area; no specific dosage or duration mentioned.
Number of subjects: 0
Study 24958044 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal drainage
Number of subjects: 24
Study 24958044 — intervention group
Group type: COMPARATOR
Intervention: Pleural drainage
Number of subjects: 24
Study 24958044 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal drainage (AVSD subset)
Number of subjects: 24
Study 24958044 — intervention group
Group type: COMPARATOR
Intervention: Pleural drainage (AVSD subset)
Number of subjects: 24
Study 24958044 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal drainage (TOF subset)
Number of subjects: 24
Study 24958044 — intervention group
Group type: COMPARATOR
Intervention: Pleural drainage (TOF subset)
Number of subjects: 24
Study 21778107 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar face images
Number of subjects: 9
Study 21778107 — intervention group
Group type: EXPERIMENTAL
Intervention: Own face images
Number of subjects: 9
Study 21778107 — intervention group
Group type: COMPARATOR
Intervention: Unfamiliar face images
Number of subjects: 9
Study 20674654 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walking Test (ISWT)
Number of subjects: 30
Study 17344605 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized pelvis traction and ultrashort wave
Number of subjects: 84
Study 17344605 — intervention group
Group type: COMPARATOR
Intervention: Computerized pelvis traction only
Number of subjects: 84
Study 17344605 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized pelvis traction, ultrashort wave, and traditional Chinese medicine iontophoresis
Number of subjects: 84
Study 17344605 — intervention group
Group type: COMPARATOR
Intervention: Group B (Computerized pelvis traction only)
Number of subjects: 84
Study 17344605 — intervention group
Group type: COMPARATOR
Intervention: Group A (Computerized pelvis traction and ultrashort wave)
Number of subjects: 84
Study 15695300 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly oral alendronate (1-2 mg/kg body weight)
Number of subjects: 22
Study 15695300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11876712 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline-containing therapy (omeprazole 20 mg twice daily, bismuth 120 mg four times daily, metronidazole 500 mg twice daily, tetracycline 500 mg four times daily for 7 days)
Number of subjects: 95
Study 11876712 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin-containing therapy (omeprazole 20 mg twice daily, bismuth 120 mg four times daily, metronidazole 500 mg twice daily, clarithromycin 500 mg twice daily for 7 days)
Number of subjects: 95
Study 12577331 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Salviae Injection (CSI) 0.5 ml/kg by intravenous dripping
Number of subjects: 18
Study 12577331 — intervention group
Group type: COMPARATOR
Intervention: Normal saline in equal volume (Control)
Number of subjects: 18
Study 9756307 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined (cc) 2 mg oestradiol valerate and 0.7 mg norethisterone acetate HRT daily
Number of subjects: 30
Study 9756307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg daily
Number of subjects: 30
Study 9756307 — intervention group
Group type: COMPARATOR
Intervention: Both types of HRT
Number of subjects: 30
Study 9756307 — intervention group
Group type: COMPARATOR
Intervention: Higher post-HRT uterine PP14 concentration
Number of subjects: 30
Study 10151073 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinopront syrup (15 g)
Number of subjects: 36
Study 10151073 — intervention group
Group type: COMPARATOR
Intervention: Triaminic (commercial standard decongestant)
Number of subjects: 36
Study 10151073 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 36
Study 10151073 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinopront syrup (1 g per year of age)
Number of subjects: 36
Study 3048053 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (75-300 micrograms daily)
Number of subjects: 20
Study 3048053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3048053 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 20
Study 30246187 — intervention group
Group type: EXPERIMENTAL
Intervention: Supracrestal implants (SC)
Number of subjects: 10
Study 30246187 — intervention group
Group type: COMPARATOR
Intervention: Bone level implants (BL)
Number of subjects: 10
Study 28441175 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 214
Study 25933099 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive armodafinil 150 mg/day
Number of subjects: 492
Study 25933099 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive armodafinil 200 mg/day
Number of subjects: 492
Study 25933099 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 492
Study 23523362 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary cancer support team (CST) intervention consisting of individualized care coordination, symptom management, education, psychosocial and spiritual supports, and advance care planning over 15 months
Number of subjects: 610
Study 23523362 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 610
Study 21551012 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental warm-up (15 min cycling from 60% to 70% of maximal heart rate, followed by 1 sprint)
Number of subjects: 2
Study 21551012 — intervention group
Group type: COMPARATOR
Intervention: Traditional warm-up (20 min cycling from 60% to 95% of maximal heart rate, followed by 4 sprints)
Number of subjects: 2
Study 19058484 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (two drops in growing concentrations of 500, 1,000, 2,000, 10,000, and 20,000 biological units)
Number of subjects: 138
Study 19058484 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 138
Study 17154743 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week group cognitive-behavioral stress management intervention
Number of subjects: 199
Study 12704348 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-5 (mepolizumab)
Number of subjects: 0
Study 12704348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10913779 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of NSAIDs (diclofenac sodium salt, fenoprofen calcium salt, ibuprofen, ketoprofen, nabumetone, sulindac)
Number of subjects: 0
Study 10913779 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of antimicrobial drugs (acyclovir, ampicillin, atovaquone, dapsone, enoxacin, ethambutol, lomefloxacin HCl, ofloxacin, pentamidine isethionate, pyrimethamine, sulfamethoxazole, tetracycline HCl, trimethoprim)
Number of subjects: 0
Study 10913779 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of drugs
Number of subjects: 0
Study 8807660 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 50 mg per day for 4 days and 100 mg per day for 8 days
Number of subjects: 8
Study 8807660 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 200 mg orally
Number of subjects: 8
Study 1564678 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive (o.c.)
Number of subjects: 82
Study 1564678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 31999489 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+LP‐L (1.7 mg/kg, low dosage of LP)
Number of subjects: 5
Study 31999489 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+LP‐M (5.2 mg/kg, middle dosage of LP)
Number of subjects: 5
Study 31999489 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+LP‐H (10.4 mg/kg, high dosage of LP)
Number of subjects: 5
Study 31999489 — intervention group
Group type: EXPERIMENTAL
Intervention: LP during RT (observation group)
Number of subjects: 5
Study 31999489 — intervention group
Group type: COMPARATOR
Intervention: RT only (control group)
Number of subjects: 5
Study 29669604 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg monotherapy)
Number of subjects: 336
Study 29669604 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 336
Study 28363814 — intervention group
Group type: EXPERIMENTAL
Intervention: recipe card plus video demonstration
Number of subjects: 141
Study 28363814 — intervention group
Group type: EXPERIMENTAL
Intervention: recipe card plus video demonstration conducted in segmented stages
Number of subjects: 141
Study 28363814 — intervention group
Group type: EXPERIMENTAL
Intervention: recipe card plus video demonstration whereby participants freely accessed video demonstrations as and when needed
Number of subjects: 141
Study 25716126 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 30
Study 25716126 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anesthetic-based balanced general anesthesia
Number of subjects: 30
Study 23788750 — intervention group
Group type: EXPERIMENTAL
Intervention: Lonaprisan 25 mg
Number of subjects: 68
Study 23788750 — intervention group
Group type: EXPERIMENTAL
Intervention: Lonaprisan 100 mg
Number of subjects: 68
Study 23788750 — intervention group
Group type: EXPERIMENTAL
Intervention: Lonaprisan (both dosages)
Number of subjects: 68
Study 20598968 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip device
Number of subjects: 279
Study 20598968 — intervention group
Group type: COMPARATOR
Intervention: Open mitral valve surgery (control)
Number of subjects: 279
Study 19730274 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized psychotherapy for suicide attempting adolescents (n = 17)
Number of subjects: 124
Study 19730274 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication algorithm (n = 14)
Number of subjects: 124
Study 19730274 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of psychotherapy and medication (n = 93)
Number of subjects: 124
Study 19730274 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 124
Study 16769264 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral 30 mg risedronate, oral 1000 mg elemental calcium, and oral 400 IU cholecalciferol
Number of subjects: 1
Study 16769264 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowly titrated anti-resorptive therapy (subcutaneous calcitonin followed by titrated doses of risedronate)
Number of subjects: 1
Study 15333854 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam and 5 mg i.v. hydrocodone
Number of subjects: 120
Study 15333854 — intervention group
Group type: COMPARATOR
Intervention: midazolam and placebo
Number of subjects: 120
Study 11761205 — intervention group
Group type: EXPERIMENTAL
Intervention: Education of practice teams about the management of depression
Number of subjects: 0
Study 9425363 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B deoxycholate (ABD; 1 mg/kg.day on days 1‐20, 21‐40 and 61‐80)
Number of subjects: 11
Study 9425363 — intervention group
Group type: COMPARATOR
Intervention: Sodium antimony gluconate (SAG; 20 mg/kg day for 20-day courses with 20-day drug-free intervals)
Number of subjects: 11
Study 8256454 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen replacement therapy
Number of subjects: 0
Study 8256454 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic steroid therapy
Number of subjects: 0
Study 3541613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine plus adjunctive magnesium sulfate
Number of subjects: 0
Study 3541613 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine plus placebo
Number of subjects: 0
Study 31665939 — intervention group
Group type: EXPERIMENTAL
Intervention: vaginal suppository progesterone
Number of subjects: 140
Study 31665939 — intervention group
Group type: EXPERIMENTAL
Intervention: tablet aspirin 80 mg
Number of subjects: 140
Study 31665939 — intervention group
Group type: COMPARATOR
Intervention: control group without any intervention
Number of subjects: 140